Calcitonin gene-related peptide - Akela Pharma

Drug Profile

Calcitonin gene-related peptide - Akela Pharma

Alternative Names: Akela CGRP; CGRP - Akela Pharma; LAB CGRP

Latest Information Update: 18 Mar 2013

Price : $50

At a glance

  • Originator University of Sherbrooke
  • Developer Akela Pharma
  • Class Antiarrhythmics; Antiasthmatics; Neuropeptides; Vasodilators
  • Mechanism of Action Calcitonin gene-related peptide agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 14 Mar 2013 Discontinued - Phase-II for Asthma in European Union (Inhalation)
  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 11 Sep 2009 CGRP is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top